GlassScriptPhysician profile
Deborah M Longwill
NPI 1518921303
$4,849.39
in general payments reported to CMS, 2019-2025
22 companies · $463 in 2025
The $463 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,598 · 2020: $105 · 2021: $1,370 · 2022: $777 · 2023: $169 · 2024: $368 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,912.62 | 2019-2022 | |
| Merz North America, INC. | $1,473.98 | 2019-2022 | |
| Abbvie INC. | $439.95 | 2023-2025 | |
| Revance Therapeutics, INC. | $264.20 | 2025 | Daxxify |
| Promius Pharma LLC | $136.65 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $126.28 | 2023-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $102.73 | 2020-2025 | |
| Organogenesis INC. | $94.50 | 2021-2025 | Puraply, Cygnus Dual |
| Galderma Laboratories, L.P. | $52.14 | 2020-2021 | |
| Pfizer INC. | $30.60 | 2019-2021 | |
| Amgen INC. | $28.82 | 2021 | |
| Genzyme Corporation | $24.50 | 2021 | |
| Verrica Pharmaceuticals INC. | $23.61 | 2024 | Ycanth |
| Janssen Biotech, INC. | $20.88 | 2020 | |
| Glenmark Therapeutics INC. | $20.00 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $19.54 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.87 | 2019 | |
| Ucb, INC. | $14.98 | 2021 | |
| Strata Skin Sciences, INC. | $13.48 | 2025 | Xtrac |
| Journey Medical Corporation | $13.32 | 2022 | |
| Mission Pharmacal Company | $12.08 | 2021 | |
| Biofrontera INC. | $6.66 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Longwill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.